100 videos

Dr Cristina SOARE

Dermatologist

Romania

I am board-certified dermatologist with a robust specialization in aesthetic medicine, dermatosurgery, and skin ultrasound. With 6 years of experience, I honed my expertise in a range of procedures, from minimally invasive cosmetic enhancements to complex dermatological surgeries. My practice is grounded in the philosophy that each patient deserves a tailored approach, blending cutting-edge techniques with traditional care principles to enhance natural beauty and promote skin health. My skill in cutaneous ultrasound stands out, providing me with detailed insights into the skin's structure, which guides me in devising precise treatment plans for my patients. I have published numerous papers in peer-reviewed journals, since my first year as a resident doctor in dermatology. Apart from my clinical work, I am in my third year as a PhD student studying actinic keratosis and squamous cell caricinomas using in vivo reflectance confocal microscopy and cutaneous ultrasound.

[Not Available].

Dec, 2018

Maedica

Mediators of Inflammation in Topical Therapy of Skin Cancers.

2019

Taking into consideration that the immune system plays a very important role in the development of melanoma and non-melanoma skin cancers, which have a high prevalence in immunosuppressed patients and after prolonged ultraviolet radiation, the interest in developing novel therapies, in particular targeting the inflammation in cancer, has increased in the past years. The latest data suggest that therapies such as imiquimod (IMQ), ingenol mebutate (IM), 5-fluorouracil (5-FU), retinoids, and nonsteroidal anti-inflammatory drugs (NSAIDs) have been used with success in the topical treatment of some cancers. Herein, we review the topical treatment targeting the inflammation in skin cancer and the mechanisms involved in these processes. Currently, various associations have shown a superior success rate than monotherapy, such as systemic acitretin and topical IMQ, topical 5-FU with tretinoin cream, or IMQ with checkpoint inhibitor cytotoxic T lymphocyte antigen 4. Novel therapies targeting Toll-like receptor-7 (TLR-7) with higher selectivity than IMQ are also of great interest. read more

Mediators of inflammation

The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments.

2018

An important function of the immune system is its ability to differentiate between healthy cells in the organism and "foreign" cells, allowing the latest to be attacked and the first ones to be conserved. The most important molecules in this process are considered to be checkpoint inhibitors. This review is focused on the association between cancer and inflammation, underlying the mechanisms of action of monoclonal antibodies that are targeting checkpoint inhibitors: ipilimumab against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and pembrolizumab and nivolumab against programmed cell death protein 1 (PD-1), their indications for treatment, and side effects. Presence of antibodies against checkpoint inhibitors shows promising results in the clinical trials in patients with types of cancer difficult to treat until now such as melanoma, non-small-cell lung cancer (NSCLC), and renal cell carcinoma, offering an increase in the overall survival rate, response rate, and progression-free rate. Resistance is now observed to emerge in patients treated with this therapy, showing the need for more studies in order to design a biomarker that will predict the type of response to immunotherapy. read more

Journal of immunology research